{"product_id":"resmed-swot-analysis","title":"ResMed SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eResMed stands out with its strong brand recognition and innovative sleep apnea solutions, but faces increasing competition and regulatory hurdles. Understanding these dynamics is crucial for navigating the evolving healthcare landscape.\u003c\/p\u003e\n\u003cp\u003eWant the full story behind ResMed's strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership in Sleep and Respiratory Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed is a dominant force in the sleep and respiratory care market, holding a commanding global leadership position. This strength is built on its comprehensive offerings for diagnosing, treating, and managing conditions like sleep apnea.  The company has seen its market share grow, partly due to challenges faced by competitors, reinforcing its advantage.\u003c\/p\u003e\n\u003cp\u003eThis leadership translates into significant brand recognition and an established presence, which are crucial in the expanding healthcare sector. ResMed’s unwavering commitment to developing patient-focused solutions further solidifies its competitive edge, allowing it to capture a substantial portion of this vital market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Product Portfolio and Digital Health Ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed's commitment to innovation is evident in its strong product pipeline, including the highly regarded AirSense 11 CPAP machine, and a diverse range of advanced masks designed for patient comfort and efficacy. This continuous investment in research and development ensures a competitive edge in the rapidly evolving sleep apnea and respiratory care market.\u003c\/p\u003e\n\u003cp\u003eThe company excels in its connected digital health ecosystem, integrating AI and machine learning to optimize therapy outcomes. Platforms like myAir and AirView provide valuable data insights, improving patient adherence and enabling remote monitoring, which is crucial for managing chronic respiratory conditions effectively.\u003c\/p\u003e\n\u003cp\u003eThis technological leadership translates into tangible market advantages. For instance, ResMed reported a revenue of $4.23 billion for the fiscal year ending June 30, 2024, reflecting strong demand driven by its innovative solutions and digital health offerings, solidifying its position as a market leader.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsistent Strong Financial Performance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed consistently showcases robust financial health, marked by strong revenue growth and expanding operating margins. For fiscal year 2025, the company reported a significant 10% increase in revenue, reaching $5.1 billion. This upward trend is further supported by a 230 basis point improvement in non-GAAP gross margin, which climbed to 60.0%, demonstrating efficient operations and pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Cash Flow and Strong Balance Sheet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed demonstrates impressive financial health, highlighted by its robust operating cash flow. This strength is underscored by the company's strategic move to a net cash position of $541 million by the end of fiscal year 2025. This financial agility is crucial for ResMed, allowing it to effectively finance key growth strategies, explore potential acquisitions, and reward its investors through dividends and share buybacks.\u003c\/p\u003e\n\u003cp\u003eThe company's strong balance sheet is a significant asset, providing a stable platform for sustained expansion and operational resilience. This financial fortitude positions ResMed favorably to navigate market dynamics and capitalize on future opportunities. The ability to self-fund initiatives without excessive reliance on external debt offers a competitive advantage and enhances long-term shareholder value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrong Cash Generation:\u003c\/strong\u003e ResMed consistently generates substantial operating cash flow.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNet Cash Position:\u003c\/strong\u003e Achieved a net cash balance of $541 million by fiscal year-end 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancial Flexibility:\u003c\/strong\u003e Enables funding of strategic initiatives and acquisitions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eShareholder Returns:\u003c\/strong\u003e Supports dividends and share repurchase programs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Vision and Global Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed's strategic vision is clearly articulated in its 2030 plan, which prioritizes innovation, operational efficiency, commercial success, and financial stability, with an ambitious goal of impacting over 500 million lives by the end of the decade. This forward-looking approach provides a strong directional compass for the company's growth initiatives.\u003c\/p\u003e\n\u003cp\u003eThe company boasts an impressive global footprint, operating in more than 140 countries, supported by a robust and well-established distribution network. This extensive reach allows ResMed to effectively penetrate diverse markets and seize opportunities presented by evolving global health landscapes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Presence:\u003c\/strong\u003e Operations in over 140 countries.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Goal:\u003c\/strong\u003e Aiming to help over 500 million people by 2030.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDistribution Network:\u003c\/strong\u003e Well-established infrastructure for broad market penetration.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Capitalization:\u003c\/strong\u003e As of early 2025, ResMed's market capitalization hovers around $30 billion, reflecting investor confidence in its global strategy and execution.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership Drives Financial Growth and Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed's market leadership in sleep and respiratory care is a significant strength, bolstered by its comprehensive product portfolio and strong brand recognition. The company's continuous investment in research and development fuels a robust product pipeline, including advanced CPAP machines and comfortable masks, ensuring a competitive edge. Furthermore, its integrated digital health ecosystem, featuring AI-powered platforms like myAir and AirView, enhances patient adherence and enables effective remote monitoring.\u003c\/p\u003e\n\u003cp\u003eResMed demonstrates exceptional financial health, characterized by consistent revenue growth and improving operating margins. For fiscal year 2025, the company reported a 10% revenue increase to $5.1 billion, with a non-GAAP gross margin rising to 60.0%. This financial strength is further evidenced by a net cash position of $541 million by fiscal year-end 2025, providing substantial flexibility for strategic investments and shareholder returns.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY 2024\u003c\/th\u003e\n\u003cth\u003eFY 2025\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$4.23 billion\u003c\/td\u003e\n\u003ctd\u003e$5.1 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-GAAP Gross Margin\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e60.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Position (End of FY)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e$541 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAnalyzes ResMed’s competitive position through key internal and external factors, highlighting its strong brand and market leadership alongside potential regulatory hurdles and emerging competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a structured framework to identify and address ResMed's market vulnerabilities and competitive threats, thereby alleviating strategic planning pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePotential Slowdown in Revenue and EPS Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnalysts are forecasting a moderation in ResMed's revenue and earnings per share (EPS) growth for fiscal years 2026 and 2027. This projected slowdown follows a period of robust historical expansion, and could potentially influence how investors perceive the company's future prospects and valuation. \u003c\/p\u003e\n\u003cp\u003eFor instance, consensus estimates suggest revenue growth could dip from an estimated 10-12% in FY2025 to a range of 6-8% in FY2026. Similarly, EPS growth might decelerate from a projected 15-18% in FY2025 to around 8-10% in FY2026. \u003c\/p\u003e\n\u003cp\u003eTo counter this anticipated deceleration, ResMed will need to effectively showcase and implement new avenues for growth. Successfully identifying and capitalizing on emerging markets or innovative product lines will be crucial in maintaining investor confidence and supporting its valuation metrics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Dependence on CPAP Device Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed's reliance on Continuous Positive Airway Pressure (CPAP) devices for sleep apnea treatment remains a notable weakness. While these devices are core to their business, a significant portion of revenue, around 60% as of recent reports, still stems from this segment. This concentration exposes the company to potential market shifts, such as the rise of alternative therapies or changes in how sleep apnea is managed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePressure on Gross Margins from External Factors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed's gross margins have been squeezed by factors like unfavorable foreign exchange rates and higher shipping expenses. For instance, in the first half of fiscal year 2024, the company noted that currency headwinds impacted its results, even as it worked to offset these through pricing and cost management.\u003c\/p\u003e\n\u003cp\u003eWhile ResMed has put strategies in place to lessen these impacts, these external pressures can still affect how profitable the company is and demand constant attention. The ongoing global economic uncertainty and the complexities of supply chains present persistent hurdles to improving profit margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVulnerabilities in Global Supply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eResMed's intricate global supply chain, despite ongoing enhancements, continues to be a point of vulnerability. Geopolitical tensions and unforeseen global events, such as the ongoing trade disputes and regional conflicts, can significantly escalate freight expenses and create shortages of essential components. For instance, in early 2024, shipping costs saw a notable uptick due to disruptions in key maritime routes, impacting inventory management for many medical device manufacturers, including those supplying ResMed.\u003c\/p\u003e\n\u003cp\u003eThese persistent disruptions directly threaten ResMed's production capabilities, potentially leading to manufacturing delays and consequently affecting the company's ability to meet market demand. This can translate into missed revenue opportunities and a negative impact on financial results. For example, a semiconductor shortage experienced globally in 2022-2023 led to production slowdowns for many tech-reliant industries, a risk that medical device manufacturers like ResMed must continually mitigate.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eIncreased Freight Costs:\u003c\/strong\u003e Global shipping rates saw an average increase of 15% in the first half of 2024 compared to the same period in 2023, driven by rerouting and capacity constraints.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eComponent Availability:\u003c\/strong\u003e Certain specialized electronic components, crucial for ResMed's advanced devices, experienced lead times extending up to 30 weeks in late 2023, a situation that continues to require careful inventory planning.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduction Capacity Limitations:\u003c\/strong\u003e Supply chain bottlenecks can directly restrict the volume of devices ResMed can produce, potentially leading to backorders and impacting market share growth.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancial Performance Impact:\u003c\/strong\u003e Extended lead times and higher logistics costs can compress profit margins, necessitating proactive cost management strategies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Past Product Recalls\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eResMed's commitment to quality is generally high, but past product issues can still cast a shadow. A notable example is the Class I recall in early 2024 concerning magnetic clips in some of their CPAP masks. This event, while handled, can unfortunately erode patient confidence and tarnish the brand's esteemed reputation.\u003c\/p\u003e\n\u003cp\u003eSuch recalls necessitate unwavering attention to product development and ongoing monitoring after products hit the market. They also tend to invite increased scrutiny from regulatory bodies, adding another layer of complexity to operations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eEarly 2024 Class I Recall:\u003c\/strong\u003e Affected certain CPAP masks due to magnetic clip issues.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Trust and Brand Reputation:\u003c\/strong\u003e Incidents like recalls can negatively impact how patients perceive ResMed's safety standards.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Scrutiny:\u003c\/strong\u003e Product recalls often lead to heightened oversight from health authorities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSleep Apnea Device Focus \u0026amp; Margin Headwinds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed's significant reliance on CPAP devices for sleep apnea, representing approximately 60% of its revenue, presents a concentration risk. This makes the company susceptible to shifts in treatment preferences or the emergence of alternative therapies for sleep apnea. Furthermore, the company has faced challenges with gross margins due to unfavorable foreign exchange rates and increased shipping expenses, as evidenced by currency headwinds impacting results in the first half of fiscal year 2024.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eResMed SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual ResMed SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. It provides a comprehensive overview of the company's internal strengths and weaknesses, alongside external opportunities and threats.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version, offering actionable insights for strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":55296999686492,"sku":"resmed-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/resmed-swot-analysis.png?v=1755789060","url":"https:\/\/pestel-analysis.com\/products\/resmed-swot-analysis","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}